Navigation Links
Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
Date:3/13/2013

Rensselaer, NY (PRWEB) March 13, 2013

The Shingo Prize for Operational Excellence, part of the Jon M. Huntsman School of Business at Utah State University, has selected the Industrial Operations and Product Supply (IOPS) group of Regeneron Pharmaceuticals, Inc. as a recipient of the Shingo Bronze Medallion.

“Receipt of the Shingo Bronze Medallion signifies an organization’s strong use of tools and techniques for business improvement,” said Robert Miller, executive director of The Shingo Prize. “Those organizations that receive the Bronze Medallion are working to develop effective systems to create continuity and consistency throughout the business entity and are on their way to true operational excellence.”

Regeneron purchased the Rensselaer site in 1994 for the purpose of large-scale manufacturing of protein-based pharmaceuticals (biologics). In 2007, Regeneron entered into a collaborative effort with the global healthcare company, Sanofi, to discover and develop antibodies using the Regeneron VelocImmune™ technology and to advance several of these drug candidates into clinical development each year. The IOPS plant at Rensselaer was tasked with increasing its manufacturing output from one or two products to 15-30 bulk products and over 100 final product forms in less than five years. In order to successfully meet the requirements, the Rensselaer site had to respond with significant operations modifications and improvements. It now has the ability to produce as many as five different drug candidates simultaneously or more than 20 in a single year, placing it among the top 15 biopharmaceutical facilities worldwide in terms of production capacity.

“As I reflect back on the last six years, I can’t help but marvel at our progress,” said Daniel P. Van Plew, senior vice president and general manager of Industrial Operations and Product Supply. “Being recognized for our efforts is for sure exciting, but not as exciting as watching this journey continue to unfold a little more each day.”

Through its operations initiatives, the IOPS group at Rensselaer has experienced, among other achievements, a 200% increase in labor productivity, a 92% decrease in product changeover time and a more than 800% increase in the number of product forms manufactured.

Regeneron’s IOPS group will receive the Shingo Bronze Medallion at the Awards Ceremony and Gala during the 25th Annual Shingo Prize International Conference, May 6-10, 2013 in Provo, Utah. The awards gala is the conclusion to this four-day event featuring a selection of workshops, plant tours, keynote speakers and breakout sessions designed to provide ongoing knowledge, insights and experience for organizations in their pursuit of operational excellence.

“In providing recognition, The Shingo Prize invites organizations to challenge early in their implementation of improvement efforts,” Miller said. “Doing so provides them valuable feedback to help accelerate their implementation. By understanding the principles we teach, organizations can begin to proactively change their culture. Culture is the key to sustainable operational excellence.”

About The Shingo Prize
The Shingo Prize for Operational Excellence is named after Japanese industrial engineer Shigeo Shingo. Dr. Shingo distinguished himself as one of the world’s thought leaders in concepts, management systems and improvement techniques that have become known as the Toyota Business System. Drawing from Dr. Shingo’s teachings, The Shingo Prize helps companies and organizations increase their efficiency and effectiveness by developing cultures that better tap the talents of their employees. It also awards and recognizes organizations that demonstrate exceptional results from applying its philosophy. Those interested in more information or in registering to attend the 25th Annual International Conference may visit http://www.shingoprize.org.

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, rheumatoid arthritis, and asthma. Those interested in more information about the company may visit http://www.regeneron.com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10524606.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
2. Regeneron Announces March 2012 Investor Conference Presentations
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
5. Introducing a New, Easy Way for Industrial Businesses to Join the Online Conversation
6. Global Markets for Enzymes in Industrial Applications
7. Global Markets for Enzymes in Industrial Applications -- Focus on Europe
8. National Defense Industrial Association (NDIA) Opens Registration For 2012 Biosurveillance Conference, Set For August 27-28 in Washington, D.C.
9. National Defense Industrial Association's (NDIA) 2012 Biosurveillance Conference To Feature Keynote Speaker Laurie Garrett, Pulitzer Prize Winner and Bestselling Author
10. BIRD - Israel-US Binational Industrial R&D Foundation to Invest $7.15 Million in Eight New Projects
11. Biomass characterization technology research highlighted in Industrial Biotechnology journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... , ... June 20, 2017 , ... ... Robbie, PhD, a well-versed leader with extensive assay development and biomarker expertise, as ... Biomedical is a Boston CRO specializing in bio-analytical assay development and sample testing ...
(Date:6/19/2017)... ... 2017 , ... As Vice President, Product Services, Mr. Guinter ... support, and client process and SOP development. , Mr. Guinter brings a wealth ... for service providers and top-tier pharmaceuticals, and as an independent consultant supported a ...
(Date:6/19/2017)... Iowa (PRWEB) , ... June 19, 2017 , ... A ... interplay among its cells and tissues by delivering pollen and nectar containing nutrients necessary ... the means to stay healthy. , Many recent indicators point to a decline in ...
(Date:6/16/2017)... (PRWEB) , ... June 16, 2017 , ... CTNext ... Entrepreneur Innovation Awards (EIA), held at The LOFT at Chelsea Piers in Stamford. , ... ideas to a panel of judges for an opportunity to secure $10,000 awards to ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
Breaking Biology News(10 mins):